Drugs / RGX-121-3102
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07236606 | Nov 2025 → Apr 2028 expected | mucopolysaccharidosis type 2 | REGENXBIO Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RGX-121-3102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07236606 ↗ |
| Target | IDS | “RGX-121 is a gene therapy which is intended to deliver a functional copy of the iduronate-2-sulfatase gene (IDS) to the central nervous system.” NCT07236606 ↗ |